StockData

Monopar Therapeutics vs Rallybio

MNPR and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNPR and RLYB compare

Monopar Therapeutics is the larger company, worth 5.8 times as much as Rallybio ($477M against $82.3M).

Rallybio scores higher on the StockData Score (10 against 7 for Monopar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNPRRLYB
Size and price
Market cap$477M$82.3M
Share price$71.06$15.29
Change, 1 year−8.9%199%
Change, 5 years193%−85.5%
Beta (5Y)0.680.01
Employees2214
StockData Score
Total score710 (better)
Valuation score02 (better)
Growth score00
Performance score12 (better)
Health score66
Dividend score00
Valuation
P/E–3.4×
P/S–190×
P/B3.6×0.9× (better)
Growth
Revenue growth (TTM)–−35.6%
Profitability
Operating margin–−5581%
Net margin–6177%
Return on equity−19.5%34.5% (better)
Return on invested capital–−718%
Financial health
Debt / equity0.000.00
Current ratio33.56 (better)28.87
Altman Z-score68.99 (better)11.42
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.7%–
Held by insiders–72.6%
Insider net buying, 12 months−$5.6M$4.2M (better)
Superinvestors holding–1
Short interest, % of float–2.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.